Abstract
Amyloid deposits occur in the forms of senile plaques (SP’s), amyloid angiopathy(AA), and plaque-like vascular changes in the brains of Alzheimer’s disease (Alz) patients. These pathological changes are important since the occurrence of these structures is correlated with the severity of the dementia. A protein consisting of 42–43 amino acids and with a molecular weight of about 4000 kd, designated as amyloid A41 or β-protein,2 has been isolated as a component of amyloid protein (Am) from AA in the Alz brain. The same A4 protein as in AA is also found commonly in various types of SP’s in Alz and Down’s syndrome.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald, and K. Beyreuther, Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proc. Natl. Acad. Sci. USA 82: 4245 (1985).
G. G. Glenner, and C. W. Wong, Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120: 885 (1984).
J. Kang, H. G. Lemaire, A. Unterbeck, J. Salbaum, C. L. Masters, K. H. Grzeschik, G. Muithaup, K. Beyreuther, and B. Muller-Hill, The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor, Nature 325: 733 (1987).
R. E. Tanzi, A. I. McClatchey, E. D. Lamperti, L. VillaKomaroff, J. F. Gusella, and R. L. Neve, Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease, Nature 311: 528 (1988).
N. Kitaguchi, Y. Takahashi. Y. Tokushima, S. Shiojiri, and H. Ito, Novel precursor of Alzheimer’s disease amyloid protein shows protease inhibitory activity, Nature 331: 530 (1988).
T. Kitamoto, K. Hikita, T. Tashima, J. Tateishi, and Y. Sato, Scrapie-associated fibrils (SAF) purification method yields amyloid proteins from systemic and cerebral amyloidosis, Biosci. Rep. 6: 459 (1986).
S.-H. Yen, A. Crowe, and D. W. Dickson, Monoclonal antibodies to Alzheimer neurofibrillary tangles, Am. J. Pathol. 120: 282 (1985).
D. J. Selkoe, M. B. Podlisny, C. L. Joachim, E. A. Vickers, G. Lee, L.C. Fritz, and T. Oltersdolf, Amyloid precursor protein of Alzheimer disease occurs as 110- to 135 kilodalton membrane-associated proteins in neural and nonneural tissues, Proc. Natl. Acad. Sci.USA 85: 7341 (1988).
H. Kawasaki, M. Utsuyama, S. Kubo, E. Moriizumi, S. Handa, K. Shigemoto, N. Ishikawa, Y. Hayashi, Y. Esaki, N. Maruyama, and K. Hirokawa, Production of monoclonal antibody against senile plaques in the human brain and its immunohistochemical application, J. Clin. Exp. Med. (Igaku no ayumi) 143: 101 (1987).
T. Ishii, and S. Haga, Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques, Acta. Neuropathol.(Berl.) 63: 296 (1984).
P. Eikelenboom, C. E. Hack, J. M. Rosemuller, and F. C. Stam, Complement activation in amyloid plaques in Alzheimer’s dementia, Virchows Archiv. B Cell Pathol. 56: 259 (1989).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Plenum Press, New York
About this chapter
Cite this chapter
Aizawa, Y. et al. (1990). Monoclonal Antibodies Against Senile Plaque Amyloid in Alzheimer’s Disease. In: Nagatsu, T., Fisher, A., Yoshida, M. (eds) Basic, Clinical, and Therapeutic Aspects of Alzheimer’s and Parkinson’s Diseases. Advances in Behavioral Biology, vol 38A. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5844-2_12
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5844-2_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5846-6
Online ISBN: 978-1-4684-5844-2
eBook Packages: Springer Book Archive